Financial Information for the Company and Its Subsidiaries (Tables)

12 Months Ended

Dec. 31, 2015

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet - December 31, 2015 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	20,437	$	27,507	$	58,716	$	—		$	106,660
Restricted cash and marketable securities	—		—		13,506		—			13,506
Accounts receivable, net	—		223,434		113,896		—			337,330
Supplies inventory	—		—		21,406		—			21,406
Prepaid and other current assets	28,739		39,046		16,062		(8,076		)	75,771
Total current assets	49,176		289,987		223,586		(8,076		)	554,673
Property and equipment, net	12,515		14,601		162,052		—			189,168
Investments in and receivables from unconsolidated affiliates	4,901,026		1,775,272		—		(6,507,128		)	169,170
Goodwill	—		1,956,741		—		2,013,469			3,970,210
Intangible assets, net	59,928		1,579,537		2,346		—			1,641,811
Other assets	4,653		1,717		17,078		(1,998		)	21,450
Total assets	$	5,027,298	$	5,617,855	$	405,062	$	(4,503,733	)	$	6,546,482
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	11,677	$	—		$	20,377
Accounts payable	2,816		3,760		29,837		(3,852		)	32,561
Accrued salaries and benefits	31,510		158,705		12,322		—			202,537
Accrued interest	30,463		—		17		—			30,480
Other accrued liabilities	13,962		76,590		32,909		(4,224		)	119,237
Total current liabilities	87,451		239,055		86,762		(8,076		)	405,192
Long-term debt	2,373,251		—		55,275		(23,396		)	2,405,130
Deferred income taxes	268,573		432,923		—		(1,998		)	699,498
Other long-term liabilities	4,560		71,509		20,114		—			96,183
Intercompany payable	—		1,228,157		—		(1,228,157		)	—
Noncontrolling interests – redeemable	—		—		63,060		112,672			175,732
Equity:
Total AmSurg Corp. equity	2,293,463		3,646,211		132,267		(3,778,478		)	2,293,463
Noncontrolling interests – non-redeemable	—		—		47,584		423,700			471,284
Total equity	2,293,463		3,646,211		179,851		(3,354,778		)	2,764,747
Total liabilities and equity	$	5,027,298	$	5,617,855	$	405,062	$	(4,503,733	)	$	6,546,482

Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	134,351	$	23,471	$	50,257	$	—		$	208,079
Restricted cash and marketable securities	—		—		10,219		—			10,219
Accounts receivable, net	—		123,772		109,281		—			233,053
Supplies inventory	—		301		19,673		—			19,974
Prepaid and other current assets	46,097		37,826		13,795		(4,818		)	92,900
Total current assets	180,448		185,370		203,225		(4,818		)	564,225
Property and equipment, net	10,391		9,972		160,085		—			180,448
Investments in and receivables from unconsolidated affiliates	3,912,804		1,587,881		—		(5,425,210		)	75,475
Goodwill	—		1,490,981		—		1,890,168			3,381,149
Intangible assets, net	67,678		1,203,218		2,983		—			1,273,879
Other assets	3,323		943		23,086		(1,466		)	25,886
Total assets	$	4,174,644	$	4,478,365	$	389,379	$	(3,541,326	)	$	5,501,062
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	10,126	$	—		$	18,826
Accounts payable	1,849		35		31,781		(4,080		)	29,585
Accrued salaries and benefits	25,035		101,395		13,614		—			140,044
Accrued interest	29,621		—		23		—			29,644
Other accrued liabilities	8,051		44,305		16,368		(738		)	67,986
Total current liabilities	73,256		145,735		71,912		(4,818		)	286,085
Long-term debt	2,206,950		—		53,648		(28,412		)	2,232,186
Deferred income taxes	207,500		404,984		—		(1,466		)	611,018
Other long-term liabilities	7,391		63,616		18,436		—			89,443
Intercompany payable	—		1,219,979		8,010		(1,227,989		)	—
Noncontrolling interests – redeemable	—		—		63,544		120,555			184,099
Equity:
Total AmSurg Corp. equity	1,679,547		2,644,051		130,206		(2,774,257		)	1,679,547
Noncontrolling interests – non-redeemable	—		—		43,623		375,061			418,684
Total equity	1,679,547		2,644,051		173,829		(2,399,196		)	2,098,231
Total liabilities and equity	$	4,174,644	$	4,478,365	$	389,379	$	(3,541,326	)	$	5,501,062

Condensed Consolidating Statement of Earnings

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	28,554		$	1,331,042	$	1,245,292		$	(38,004	)	$	2,566,884
Operating expenses:
Salaries and benefits	69,102			937,484		308,313			(507		)	1,314,392
Supply cost	—			2,436		181,866			(80		)	184,222
Other operating expenses	24,682			145,369		265,160			(37,417		)	397,794
Transaction costs	1,762			6,562		—			—			8,324
Depreciation and amortization	3,912			61,658		31,923			—			97,493
Total operating expenses	99,458			1,153,509		787,262			(38,004		)	2,002,225
Gain (loss) on deconsolidations	—			37,350		(656		)	—			36,694
Equity in earnings of unconsolidated affiliates	349,139			251,093		—			(584,080		)	16,152
Operating income	278,235			465,976		457,374			(584,080		)	617,505
Interest expense, net	41,140			77,947		2,499			—			121,586
Earnings from continuing operations before income taxes	237,095			388,029		454,875			(584,080		)	495,919
Income tax expense	73,159			38,891		1,740			—			113,790
Net earnings from continuing operations	163,936			349,138		453,135			(584,080		)	382,129
Net loss from discontinued operations	(989		)	—		(24		)	—			(1,013		)
Net earnings	162,947			349,138		453,111			(584,080		)	381,116
Net earnings attributable to noncontrolling interests	—			—		218,169			—			218,169
Net earnings attributable to AmSurg Corp. shareholders	162,947			349,138		234,942			(584,080		)	162,947
Preferred stock dividends	(9,056		)	—		—			—			(9,056		)
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	349,138	$	234,942		$	(584,080	)	$	153,891
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	154,880		$	349,138	$	234,954		$	(584,080	)	$	154,892
Loss from discontinued operations, net of income tax	(989		)	—		(12		)	—			(1,001		)
Net earnings attributable to AmSurg Corp. common shareholders	$	153,891		$	349,138	$	234,942		$	(584,080	)	$	153,891

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	24,773		$	508,572	$	1,112,940		$	(24,336	)	$	1,621,949
Operating expenses:
Salaries and benefits	65,697			350,615		284,050			(5,786		)	694,576
Supply cost	—			1,292		163,004			—			164,296
Other operating expenses	18,667			53,413		231,398			(18,550		)	284,928
Transaction costs	29,004			4,886		—			—			33,890
Depreciation and amortization	4,044			25,610		30,690			—			60,344
Total operating expenses	117,412			435,816		709,142			(24,336		)	1,238,034
Gain on deconsolidation	—			3,411		—			—			3,411
Equity in earnings of unconsolidated affiliates	237,657			211,889		—			(442,508		)	7,038
Operating income	145,018			288,056		403,798			(442,508		)	394,364
Interest expense, net	47,997			33,026		2,262			—			83,285
Debt extinguishment costs	16,887			—		—			—			16,887
Earnings from continuing operations before income taxes	80,134			255,030		401,536			(442,508		)	294,192
Income tax expense	29,166			17,373		1,564			—			48,103
Net earnings from continuing operations	50,968			237,657		399,972			(442,508		)	246,089
Net earnings (loss) from discontinued operations	2,733			—		(4,029		)	—			(1,296		)
Net earnings	53,701			237,657		395,943			(442,508		)	244,793
Net earnings attributable to noncontrolling interests	—			21		191,071			—			191,092
Net earnings attributable to AmSurg Corp. shareholders	53,701			237,636		204,872			(442,508		)	53,701
Preferred stock dividends	(4,503		)	—		—			—			(4,503		)
Net earnings attributable to AmSurg Corp. common shareholders	$	49,198		$	237,636	$	204,872		$	(442,508	)	$	49,198
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	46,465		$	237,636	$	209,184		$	(442,508	)	$	50,777
Earnings (loss) from discontinued operations, net of income tax	2,733			—		(4,312		)	—			(1,579		)
Net earnings attributable to AmSurg Corp. common shareholders	$	49,198		$	237,636	$	204,872		$	(442,508	)	$	49,198

Condensed Consolidating Statement of Earnings - Year Ended December 31, 2013 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	24,167	$	—	$	1,050,547		$	(17,518	)	$	1,057,196
Operating expenses:
Salaries and benefits	61,038		—		267,014			(467		)	327,585
Supply cost	—		—		153,126			—			153,126
Other operating expenses	22,360		—		211,192			(17,051		)	216,501
Transaction costs	300		—		—			—			300
Depreciation and amortization	3,186		—		29,214			—			32,400
Total operating expenses	86,884		—		660,546			(17,518		)	729,912
Gain on deconsolidation	—		2,237		—			—			2,237
Equity in earnings of unconsolidated affiliates	207,199		204,962		—			(409,010		)	3,151
Operating income	144,482		207,199		390,001			(409,010		)	332,672
Interest expense, net	27,282		—		2,243			—			29,525
Earnings from continuing operations before income taxes	117,200		207,199		387,758			(409,010		)	303,147
Income tax expense	47,139		—		1,515			—			48,654
Net earnings from continuing operations	70,061		207,199		386,243			(409,010		)	254,493
Net earnings from discontinued operations	2,642		—		4,409			—			7,051
Net earnings	72,703		207,199		390,652			(409,010		)	261,544
Net earnings attributable to noncontrolling interests	—		—		188,841			—			188,841
Net earnings attributable to AmSurg Corp. common shareholders	$	72,703	$	207,199	$	201,811		$	(409,010	)	$	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	70,061	$	207,199	$	202,759		$	(409,010	)	$	71,009
Earnings (loss) from discontinued operations, net of income tax	2,642		—		(948		)	—			1,694
Net earnings attributable to AmSurg Corp. common shareholders	$	72,703	$	207,199	$	201,811		$	(409,010	)	$	72,703

Condensed Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	40,432		$	353,932		$	489,820		$	(346,225	)	$	537,959
Cash flows from investing activities:
Acquisitions and related transactions	(757,775		)	(969,259		)	—			764,345			(962,689		)
Acquisition of property and equipment	(5,876		)	(22,988		)	(31,441		)	—			(60,305		)
Proceeds from sale of interests in surgery centers	—			7,114			—			—			7,114
Purchases of marketable securities	—			—			(3,984		)	—			(3,984		)
Maturities of marketable securities	—			—			4,233			—			4,233
Other	—			(2,927		)	1,733			—			(1,194		)
Net cash flows used in investing activities	(763,651		)	(988,060		)	(29,459		)	764,345			(1,016,825		)
Cash flows from financing activities:
Proceeds from long-term borrowings	546,000			—			14,133			—			560,133
Repayment on long-term borrowings	(379,700		)	—			(12,886		)	—			(392,586		)
Distributions to owners, including noncontrolling interests	—			(109,862		)	(451,262		)	346,225			(214,899		)
Capital contributions	—			757,775			—			(757,775		)	—
Proceeds from common stock offering	466,777			—			—			—			466,777
Payments of equity issuance costs	(19,058		)	—			—			—			(19,058		)
Financing cost incurred	(1,101		)	—			(10		)	—			(1,111		)
Changes in intercompany balances with affiliates, net	5,016			—			(5,016		)	—			—
Other financing activities, net	(8,629		)	(9,749		)	3,139			(6,570		)	(21,809		)
Net cash flows provided by (used in) financing activities	609,305			638,164			(451,902		)	(418,120		)	377,447
Net increase (decrease) in cash and cash equivalents	(113,914		)	4,036			8,459			—			(101,419		)
Cash and cash equivalents, beginning of period	134,351			23,471			50,257			—			208,079
Cash and cash equivalents, end of period	$	20,437		$	27,507		$	58,716		$	—		$	106,660

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	96,681		$	298,415		$	430,880		$	(413,605	)	$	412,371
Cash flows from investing activities:
Acquisitions and related transactions	(2,124,124		)	(2,188,191		)	1,520			2,126,737			(2,184,058		)
Acquisition of property and equipment	(7,877		)	(9,933		)	(22,407		)	—			(40,217		)
Proceeds from sale of interests in surgery centers	—			7,069			—			—			7,069
Purchases of marketable securities	—			—			(6,474		)	—			(6,474		)
Maturities of marketable securities	—			—			3,486			—			3,486
Other	(3,068		)	(6,594		)	4,721			—			(4,941		)
Net cash flows used in investing activities	(2,135,069		)	(2,197,649		)	(19,154		)	2,126,737			(2,225,135		)
Cash flows from financing activities:
Proceeds from long-term borrowings	2,040,000			—			8,958			—			2,048,958
Repayment on long-term borrowings	(396,493		)	—			(11,982		)	—			(408,475		)
Distributions to owners, including noncontrolling interests	—			(202,247		)	(401,455		)	413,605			(190,097		)
Capital contributions	—			2,124,124			—			(2,124,124		)	—
Proceeds from preferred stock offering	172,500			—			—			—			172,500
Proceeds from common stock offering	439,875			—			—			—			439,875
Payments of equity issuance costs	(24,494		)	—			—			—			(24,494		)
Financing cost incurred	(65,811		)	—			—			—			(65,811		)
Changes in intercompany balances with affiliates, net	2,965			—			(2,965		)	—			—
Other financing activities, net	(2,513		)	828			1,845			(2,613		)	(2,453		)
Net cash flows provided by (used in) financing activities	2,166,029			1,922,705			(405,599		)	(1,713,132		)	1,970,003
Net increase in cash and cash equivalents	127,641			23,471			6,127			—			157,239
Cash and cash equivalents, beginning of period	6,710			—			44,130			—			50,840
Cash and cash equivalents, end of period	$	134,351		$	23,471		$	50,257		$	—		$	208,079

Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	45,127		$	208,773		$	426,572		$	(347,648	)	$	332,824
Cash flows from investing activities:
Acquisitions and related transactions	—			(74,288		)	—			694			(73,594		)
Acquisition of property and equipment	(3,693		)	—			(25,163		)	—			(28,856		)
Proceeds from sale of interests in surgery centers	—			3,553			—			—			3,553
Other	—			159			—			—			159
Net cash flows used in investing activities	(3,693		)	(70,576		)	(25,163		)	694			(98,738		)
Cash flows from financing activities:
Proceeds from long-term borrowings	152,700			—			9,504			—			162,204
Repayment on long-term borrowings	(188,081		)	—			(14,002		)	—			(202,083		)
Distributions to owners, including noncontrolling interests	—			(138,875		)	(392,922		)	347,648			(184,149		)
Changes in intercompany balances with affiliates, net	88			—			(88		)	—			—
Other financing activities, net	(6,690		)	678			1,090			(694		)	(5,616		)
Net cash flows used in financing activities	(41,983		)	(138,197		)	(396,418		)	346,954			(229,644		)
Net increase (decrease) in cash and cash equivalents	(549		)	—			4,991			—			4,442
Cash and cash equivalents, beginning of period	7,259			—			39,139			—			46,398
Cash and cash equivalents, end of period	$	6,710		$	—		$	44,130		$	—		$	50,840